Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide in Short Bowel Syndrome
NCT03408132Phase 2Completed
- Sponsor
- GLyPharma Therapeutic
- Start
- May 2018
- Primary completion
- Oct 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apraglutide in short bowel syndrome (SBS), sponsored by GLyPharma Therapeutic. Primary endpoint: Incidence of treatment-emergent adverse events. Started May 2018; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT03408132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03408132.